Buchumschlag

Effect of Galectin 3 on aldosterone-associated risk of cardiovascular mortality in patients undergoing coronary angiography

Recent experimental studies have suggested that galectin-3 has an interaction with aldosterone, and modifies its adverse effects. We therefore aimed to elucidate whether the relationship between plasma aldosterone concentrations (PACs) and long-term fatal cardiovascular (CV) events would depend on p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Grübler, Martin R. (VerfasserIn) , Delgado Gonzales de Kleber, Graciela (VerfasserIn) , Kleber, Marcus E. (VerfasserIn) , Hartaigh, Briain O. (VerfasserIn) , de Boer, Rudolf Allert (VerfasserIn) , Verheyen, Nicolas (VerfasserIn) , Keppel, Martin (VerfasserIn) , Schmid, Johannes (VerfasserIn) , Siontis, George C. M. (VerfasserIn) , Räber, Lorenz (VerfasserIn) , Pieske, Burkert (VerfasserIn) , Pilz, Stefan (VerfasserIn) , Tomaschitz, Andreas (VerfasserIn) , März, Winfried (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: July 15 2020
In: The American journal of cardiology
Year: 2020, Jahrgang: 127, Pages: 9-15
ISSN:1879-1913
DOI:10.1016/j.amjcard.2020.04.017
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.amjcard.2020.04.017
Volltext
Verfasserangaben:Martin Robert Grübler, Graciela Delgado, Marcus Kleber, Briain O. Hartaigh, Rudolf Allert de Boer, Nicolas Verheyen, Martin Keppel, Johannes Schmid, George C. M. Siontis, Lorenz Räber, Burkert Pieske, Stefan Pilz, Andreas Tomaschitz, and Winfried März
Beschreibung
Zusammenfassung:Recent experimental studies have suggested that galectin-3 has an interaction with aldosterone, and modifies its adverse effects. We therefore aimed to elucidate whether the relationship between plasma aldosterone concentrations (PACs) and long-term fatal cardiovascular (CV) events would depend on plasma galectin-3 levels. A total of 2,457 patients (median age: 63.5 [interquartile range (IQR) = 56.3 to 70.6] years, 30.1 % women) from the LUdwigshafen RIsk and Cardiovascular Health study, with a median follow-up of 9.9 (IQR = 8.5 to 10.7) years, were included. We tested the interaction between aldosterone and galectin-3 for CV-mortality using a multivariate Cox proportional hazard model, reporting hazard ratios (HRs) with 95% confidence intervals (95 % CIs). Adjustments for multiple CV risk factors as well as medication use were included. Mean PAC was 79.0 (IQR = 48.0 to 124.0) pg/ml and there were 558 (16.8%) CV deaths. There was a significant interaction between PAC and galectin-3 (p = 0.021). When stratifying patients by the median galectin-3, there was a significant association between aldosterone and CV-mortality for those above (HR per 1 standard deviation = 1.14; 95 % CI [1.01 to 1.30], p = 0.023), but not below the cut-off value (HR per 1 standard deviation = 1.00; 95 % CI [0.87 to 1.15], p = 0.185). In conclusion, the current study demonstrates for the first time a modifying effect of galectin-3 on the association between aldosterone and CV-mortality risk in humans. These findings indicate that galectin-3 is an intermediate between aldosterone and adverse outcomes. (C) 2020 The Author(s). Published by Elsevier Inc.
Beschreibung:Gesehen am 12.05.2021
Beschreibung:Online Resource
ISSN:1879-1913
DOI:10.1016/j.amjcard.2020.04.017

Ähnliche Einträge